Interpace Biosciences Inc
OTC:IDXG
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Interpace Biosciences Inc
OTC:IDXG
|
6.3m USD | 0.3 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
92.4B EUR | 4.8 | |
US |
Cigna Corp
NYSE:CI
|
97.6B USD | 4.7 | ||
US |
CVS Health Corp
NYSE:CVS
|
69.7B USD | 2.2 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17.9B USD | 6.1 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
16.2B EUR | 5.4 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.6B USD | 6.2 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
12.2B EUR | 4.4 | |
DE |
Fresenius Medical Care AG
XMUN:FME
|
12B EUR | 4.3 | ||
US |
DaVita Inc
NYSE:DVA
|
12.1B USD | 5.2 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 128.5 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.